EWTX (Edgewise Therapeutics) Beta: 0.5298 (As of Sep. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

EWTX Edgewise Therapeutics Inc EWTX
28 GF Score
Price $43.07
! 3 Warning Signs
View Full Analysis

What is Edgewise Therapeutics Beta?

Edgewise Therapeutics EWTX +2.71% 28 Beta is 0.5298 as of Sep. 05, 2026. GuruFocus rates EWTX with a GF Score™ of 28/100. The stock has 3 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-09-05), Edgewise Therapeutics's Beta is 0.5298.


Edgewise Therapeutics  (NAS:EWTX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Edgewise Therapeutics Beta Related Terms


Edgewise Therapeutics Beta Historical Data

* Premium members only.

The historical data trend for Edgewise Therapeutics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Edgewise Therapeutics Beta Chart

Edgewise Therapeutics Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial 0.00 0.00 0.00 0.50 0.57

Edgewise Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.44 0.57 0.52 0.55

EWTX vs DYN, PBLS, CELC: Beta Comparison

For the Biotechnology subindustry, Edgewise Therapeutics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Edgewise Therapeutics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Edgewise Therapeutics's Beta distribution charts can be found below:

* The bar in red indicates where Edgewise Therapeutics's Beta falls into.


EWTX
28GF Score
Edgewise Therapeutics Inc EWTX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Edgewise Therapeutics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.5298 mean?
Edgewise Therapeutics (EWTX) has a Beta of 0.5298 as of Sep. 05, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Edgewise Therapeutics and its competitors.
Is Edgewise Therapeutics' Beta too high?
Edgewise Therapeutics' current Beta is 0.5298. Overall, Edgewise Therapeutics has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Edgewise Therapeutics' Beta compare to DYN and PBLS?
Edgewise Therapeutics' Beta of 0.5298 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Edgewise Therapeutics and its competitors. Edgewise Therapeutics's current Beta is 0.5298. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Edgewise Therapeutics stock overvalued right now?
Edgewise Therapeutics (EWTX) has a current Beta of 0.5298. The current Beta is 0.5298. Edgewise Therapeutics' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Edgewise Therapeutics (EWTX), the current Beta is 0.5298 as of Sep. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Edgewise Therapeutics Business Description

Address 1715 38th Street, Boulder, CO, USA, 80301
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is developing novel therapeutics for muscular dystrophies and serious cardiac conditions. The company's product candidates are Sevasemten, EDG-7500, EDG-003, and EDG-15400. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies, including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company's products are currently in different stages of their development, being developed to target key muscle proteins and modulators to address a broad array of muscle diseases.
28GF Score

Get the complete analysis for EWTX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$43.07
Price